Neural Correlates In Mild Alzheimer's Disease

A Single Center Study To Examine Neural Correlates Of Cognition In Subjects With Mild Alzheimer's Disease After Three Months Of Open Label Donepezil HCl (Aricept® ) Treatment

The objective of this study was to identify neural correlates of cognitive improvement after 3 months of donepezil hydrochloride treatment using either or both of two functional magnetic resonance imaging (fMRI) measures - the functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion; in the Medial Temporal Lobe (MTL) network in subjects in the early stage of Alzheimer's Disease (AD).

Inclusion Criteria:

• Men and women, aged 50 and older with mild Alzheimer's disease (MMSE scores of 20 to 30 are allowed).
• Diagnostic evidence of Alzheimer's disease.
• Previous use of cholinesterase inhibitors (other than Aricept) and memantine allowed.

Exclusion Criteria:

• Prior use of Aricept, pacemakers and insulin dependent diabetes are not allowed.